Anthera Pharmaceuticals Inc (NASDAQ:ANTH)
Anthera Pharmaceuticals Inc (NASDAQ:ANTH) shares closed up 10%, and had two closing days above the $2 level for the first time since May of 2017. The catalyst for the stock’s upward momentum, on a day when markets sold off, seems to be an article authored by a CFA specializing in the biotech space. The analyst rates the shares a “Buy”.
Anthera Pharmaceuticals Inc (NASDAQ:ANTH) is a biopharmaceutical company that develops and commercializes therapies to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. Anthera has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod. Sollpura is a non-porcine investigational Pancreatic Enzyme Replacement Therapy intended for the treatment of patients suffering from Exocrine Pancreatic Insufficiency, often seen in patients with cystic fibrosis.
Analysts on Anthera
Three analysts follow Anthera Pharmaceuticals Inc (NASDAQ:ANTH). One rates ANTH as a “Strong Buy”, while the other two rate the shares as a “Hold”. The analysts have a consensus, one-year price target of $2.00 on the shares – $0.31 below today’s close. For FY2017, analysts are projecting an EPS loss of (-$3.34).
ANTH Stock Performance
For the year, ANTH stock is down over 85%. However, the shares are up 45% for the past month.
In 2015, Anthera posted sales of $3.2 million but for 2016 the figure was a disappointing $100,000. Earnings have been disappointing as well. In 2012, the biotech firm reported an earnings loss of (-$50.19). The next year the loss was (-$13.52), followed in 2014 by a loss of (-$10.88), then (-$7.91) for 2015, and in 2016, the loss was (-$12.87).
There are a number of short-sellers on ANTH stock. Their short positions represent 15% of the stock’s float.
I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.
Don’t miss out! Stay informed on $ANTH and receive breaking news on other hot stocks by signing up for our free newsletter!
About the author: James Marion is a University of Houston student studying Business with a concentration in Finance. James has interned with several investment professionals and hopes to pursue a career as a professional stock analyst after graduation.